Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société MERCK & CO., INC.
08:35aMerck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Mo..
AQ
06:51aEuropean Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for P..
BU
06:46aEuropean Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as Fi..
BU
11/26Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Mo..
BU
11/24Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference
BU
11/23MERCK : Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluati..
PU
11/23Health Canada Approves KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for t..
AQ
11/22Merck Completes Acquisition of Acceleron Pharma Inc.
BU
11/22Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
AQ
11/22Supplying Covid-19 Pills At Lower Cost Is Only Part of What Poorer Countries Need
AQ
11/19Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
BU
11/18Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combinat..
BU
11/18FDA Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients..
BU
11/17Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Ten..
BU
11/17Merck and Ridgeback to Present Phase 3 Data for Molnupiravir, an Investigational Oral C..
BU
11/12Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO (vericiguat) in Patients..
AQ
11/11HOOKIPA Pharma Reports Third Quarter 2021 Financial Results and Recent Highlights
AQ
11/11Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® (vericiguat) in Patient..
BU
11/10Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Mol..
BU
11/09Merck and Ridgeback Announce U.S. Government to Purchase 1.4 Million Additional Courses..
BU
11/08Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tende..
BU
11/07UK to roll out antiviral Covid pill as soon as this month
AQ
11/05MERCK & CO., INC. Management's Discussion and Analysis of Financial Condition and Resu..
AQ
11/05Merck and Ridgeback's Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First..
AQ
11/04Merck and Ridgeback's Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First..
BU
11/01Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension o..
AQ
11/01New Research for KEYTRUDA (pembrolizumab) at Society for Melanoma Research (SMR) 2021 C..
AQ
10/31New Research for KEYTRUDA® (pembrolizumab) at Society for Melanoma Research (SMR) 2021 ..
BU
10/29Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension o..
BU
10/29Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy (sacituzu..
AQ
10/29BIOSTOCK : Evaxion Biotech to test EVX-01 in collaboration with Merck & Co.
AQ
10/28Merck envisions billions from COVID-19 treatment sales
AQ
10/28Thinking about trading options or stock in Apple, Mastercard, Merck, Atlassian, or Baid..
PR
10/283Q21 Merck Earnings Presentation
PU
10/283Q21 Other Financial Disclosures (Excel)
PU
10/28MERCK : Q3 Earnings Snapshot
AQ
10/283Q21 Merck Other Financial Disclosures
PU
10/28Merck Announces Third-Quarter 2021 Financial Results - Form 8-K
PU
10/28Merck Announces Third-Quarter 2021 Financial Results
BU
10/27SHAREHOLDER ALERT : WeissLaw LLP Reminds COLB, XLRN, ACBI. and ECHO Shareholders About Its..
PR
10/27Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Sa..
BU
10/27The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir..
BU
10/26Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen o..
BU
10/25MERCK : European Commission Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy as..
AQ
10/25MERCK : Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investi..
BU
10/25MERCK : and Ridgeback Announce Initiation of a Rolling Review by the European Medicines Ag..
BU
10/22MERCK : European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy a..
BU
10/21MERCK : CDC ACIP Unanimously Votes to Provisionally Recommend Merck's VAXNEUVANCE (Pneumoc..
AQ
10/20MERCK : CDC ACIP Unanimously Votes to Provisionally Recommend Merck's VAXNEUVANCE™ (..
BU
10/19MERCK : Issues Voluntary Nationwide Recall of CUBICIN® (daptomycin for injection) 500 mg, ..
BU
10/15MERCK : and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Plus LEN..
BU
10/15MERCK : Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conj..
BU
10/13MERCK : FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without ..
BU
10/13Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV (enfo..
AQ
10/12MERCK : Begins Tender Offer to Acquire Acceleron Pharma Inc.
BU
10/11MERCK : and Ridgeback Announce Submission of Emergency Use Authorization Application to th..
BU
10/07SHAREHOLDER ALERT : WeissLaw LLP Reminds XLRN, JMP, ECHO, and KDMN Shareholders About Its ..
PR
10/06MERCK : and Emmy-Nominated Actress Yvonne Orji Unveil Uncovering TNBC, Highlighting the Ch..
AQ
10/05MERCK :  Merck and Emmy-Nominated Actress Yvonne Orji Unveil Uncovering TNBC, Highlighting..
BU
10/04MERCK : Thinking about trading options or stock in NetApp, Merck, DuPont de Nemours, Ford,..
PR
10/04MERCK : and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Ho..
AQ
10/03MERCK : Tokyo stocks open higher as COVID drug boosts economic recovery hopes
AQ
10/01Merck, IFF rise; Lordstown Motors, PDC Energy fall
AQ
10/01MERCK : Thinking about trading options or stock in Carnival Corp, Atea Pharmaceuticals, AM..
PR
10/01MERCK : says experimental pill cuts worst effects of COVID-19
AQ
10/01MERCK : and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Ho..
BU
09/30ACCELERON PHARMA : Merck spends $11.5B for Acceleron, possible blockbuster drug
AQ
09/30MERCK : to Acquire Acceleron Pharma Inc.
BU
09/29MERCK : Announces Appointment of Thomas H. Glocer as Independent Lead Director
BU
09/28MERCK : Announces KEYTRUDA (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) i..
AQ
09/28MERCK : to Hold Third-Quarter 2021 Sales and Earnings Conference Call on October 28
BU
09/27MERCK : Announces KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) ..
BU
09/27MERCK : LYNPARZA (olaparib) in combination with abiraterone significantly delayed disease ..
AQ
09/27MERCK : LYNPARZA (olaparib) in Combination With Abiraterone Significantly Delayed Disease ..
AQ
09/24MERCK : LYNPARZA® (olaparib) in Combination With Abiraterone Significantly Delayed Disease..
BU
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on MERCK & CO., INC.